KYAN Technologies uses a small set of live-cell experiments and its own AI to rank more than 1,500 personalised drug combinations for a patient's cancer.
KYAN Technologies, based in Singapore with US operations, markets Optim.AI, a functional precision medicine platform that tests a patient's live cancer cells against drugs and uses its algorithm to evaluate and rank over 1,500 personalised combinations. Physician-ordered.
Shares Functional (ex vivo) drug testing and the tag fcct-directory.
Shares Functional (ex vivo) drug testing and the tag fcct-directory.
Shares Functional (ex vivo) drug testing and the tag fcct-directory.
Shares Functional (ex vivo) drug testing and the tag fcct-directory.
Shares Functional (ex vivo) drug testing and the tag fcct-directory.
Shares Functional (ex vivo) drug testing and the tag fcct-directory.
Shares Functional (ex vivo) drug testing and the tag fcct-directory.
Shares Functional (ex vivo) drug testing and the tag fcct-directory.